<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883450</url>
  </required_header>
  <id_info>
    <org_study_id>12135</org_study_id>
    <secondary_id>R01CA230442</secondary_id>
    <nct_id>NCT04883450</nct_id>
  </id_info>
  <brief_title>PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer</brief_title>
  <acronym>PRO-TECT</acronym>
  <official_title>PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conduct a prospective study to assess the accuracy of a pancreatic cancer risk prediction&#xD;
      model.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to establish a platform for development and implementation of a&#xD;
      data-driven risk model for detection of early stage pancreatic cancer within an integrated&#xD;
      health care setting. Patients at increased risk for pancreatic cancer as identified by the&#xD;
      risk model will be invited to participate in a prospective study to assess the accuracy of&#xD;
      this approach for detection of early stage pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pancreatic ductal adenocarcinoma in the high predicted risk group</measure>
    <time_frame>18-Month</time_frame>
    <description>Enrolled subjects will be followed for 18 months to determine the incidence rate of PDAC</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Risk of pancreatic cancer</arm_group_label>
    <description>Subjects with an increased predicted 18-month risk of pancreatic cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>All enrolled participants will undergo magnetic resonance imaging (MRI) at their Baseline and 18-Month follow-up visit</description>
    <arm_group_label>Risk of pancreatic cancer</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (plasma, serum and Buffy coat) and Urine samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Kaiser Permanente Southern California with at least 12 months prior to recruitment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must have 6 months of membership&#xD;
&#xD;
          2. Patient has a measure for weight, A1c, and ALT within the past 6 months&#xD;
&#xD;
          3. Patient must have an increased predicted 18-month risk of pancreatic cancer based on&#xD;
             the PRO-TECT model&#xD;
&#xD;
          4. Speaks English or Spanish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous or current history of pancreatic cancer&#xD;
&#xD;
          2. Metastatic cancer&#xD;
&#xD;
          3. Current active cancer or undergoing chemotherapy for cancer&#xD;
&#xD;
          4. Currently pregnant or breastfeeding&#xD;
&#xD;
          5. Class IV heart failure&#xD;
&#xD;
          6. Cirrhosis with ascites and/or varices&#xD;
&#xD;
          7. Currently in a skilled nursing facility or under hospice care&#xD;
&#xD;
          8. Has metal parts or implanted devices in the body, such as a pacemaker, defibrillator,&#xD;
             or shrapnel&#xD;
&#xD;
          9. End stage renal disease&#xD;
&#xD;
         10. Cognitive impairment such that the person is unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bechien U Wu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Lustigova, MPH</last_name>
    <phone>1-833-242-8504</phone>
    <email>protect@kp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente Southern California</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Lustigova, MPH</last_name>
      <phone>833-242-8504</phone>
      <email>protect@kp.org</email>
    </contact>
    <investigator>
      <last_name>Bechien U Wu, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

